Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Three drugs accepted for use in NHS Scotland, but six rejected

By News team

Filgrastim (Nivestim; Hospira) is one of three drugs that have been approved for use in NHS Scotland following the Scottish Medicines Consortium’s latest round of appraisals (February 2011). The medicine is accepted for use for its licensed indications, which relate to neutropenia.

Capsaicin cutaneous patches (Qutenza; Astellas) are accepted for restricted use for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.

Treatment with the patches must be under the supervision of a specialist in pain management, and is restricted to adults with post-herpetic neuralgia who have not achieved adequate pain relief from, or have not tolerated, conventional first- and second-line treatments.

Rituximab (Mabthera; Roche) is also accepted for restricted use for the maintenance treatment of follicular lymphoma in patients responding to induction therapy with the drug plus chemotherapy.

Six medicines were not recommended by the consortium. Golimumab (Simponi; Merck, Sharp and Dohme) was rejected for treatment of psoriatic arthritis in adults with poor response to disease-modifying antirheumatic drugs because its manufacturer did not provide a sufficiently robust economic case.

The miconazole muco-adhesive buccal tablet (Loramyc; Therabel Pharma) was rejected for use for the treatment of oropharyngeal candidiasis in immunocompromised patients because the SMC was not convinced by the clinical and economic cases presented.

Trastuzumab (Herceptin; Roche) was rejected for use for the treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach because it was not considered value for money.

Other medicines not accepted were colesevelam (Cholestagel; Genzyme Therapeutics) for hypercholesterolaemia, fenticonazole (Ginoxin; Recordati Pharmaceuticals) and ivabradine (Procoralan; Servier Laboratories) because the marketing authorisation holders did not make submissions to the SMC.

Citation: The Pharmaceutical Journal URI: 11068280

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Scottish money

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.